Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors

PURPOSE: To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG). METHODS: 17DMAG was given intravenously over 1 hour daily for 5 days (schedule A) or daily for 3 days (schedule B) every 3 weeks. Plasma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ramanathan, Ramesh K., Egorin, Merrill J., Erlichman, Charles, Remick, Scot C., Ramalingam, Suresh S., Naret, Cynthia, Holleran, Julianne L., TenEyck, Cynthia J., Ivy, S. Percy, Belani, Chandra P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2010
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849772/
https://ncbi.nlm.nih.gov/pubmed/20177028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.0415
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars